Jade Biosciences Announces Preclinical Data for JADE301, Plans Phase 1

What Happened

• On September 30, 2026 Jade Biosciences announced preclinical results for JADE301, a fully human IgG1 YTE‑modified monoclonal antibody that selectively neutralizes interferon‑beta (IFN‑β) for dermatomyositis (DM). Jade reported strong in vitro potency and favorable nonclinical pharmacokinetics and tolerability, and said it expects to start a placebo‑controlled, single ascending‑dose Phase 1 subcutaneous (SC) trial in 24 healthy volunteers in Q4 2026, with interim data anticipated in the second half of 2027.

Key Details

• Binding and potency: JADE301 KD = 11.3 pM for IFN‑β; IC50 = 13 pM for pSTAT inhibition in a human immune cell line and IC50 = 11 pM for MX‑1 suppression in human dermal fibroblasts. Reported as ~2.5–8× more potent than a dazukibart comparator in those assays.
• Pharmacokinetics: ~30‑day half‑life after 30 mg/kg IV in non‑human primates (NHPs); ~25‑day half‑life after SC dosing in NHPs. Translational modeling predicts human SC bioavailability ~73–75% (vs. reported dazukibart SC bioavailability ~43–44%).
• Tissue exposure and safety: JADE301 muscle concentrations ~1–4% of serum (typical for mAbs). In a GLP NHP toxicology study with SC dosing every two weeks at 0, 50, 100 and 200 mg/kg, JADE301 was well tolerated with no treatment‑related clinical, lab, or histopathology findings.
• Clinical plan: Placebo‑controlled, single ascending‑dose Phase 1 in 24 healthy volunteers to assess safety, tolerability, PK and immunogenicity; initiation expected Q4 2026, interim data H2 2027.

Why It Matters

• These preclinical results provide data points investors use to track early value drivers: high potency vs. a comparator, long predicted dosing interval (supporting less frequent SC dosing), and clean NHP safety at tested doses. The planned Phase 1 trial timeline (start in Q4 2026; interim data H2 2027) gives clear near‑term clinical milestones.
• As with all preclinical and early clinical claims, Jade’s statements are forward‑looking and subject to risks (e.g., clinical trial delays, different human results); investors should watch for Phase 1 safety/PK readouts and any regulatory or enrollment updates.